Published in Bioconjug Chem on September 25, 2012
A general method for artificial metalloenzyme formation through strain-promoted azide-alkyne cycloaddition. Chembiochem (2013) 0.96
Chemically programmed antibodies. Trends Biotechnol (2014) 0.92
Antibody conjugation via one and two C-terminal selenocysteines. Methods (2013) 0.91
An evolved Mxe GyrA intein for enhanced production of fusion proteins. ACS Chem Biol (2014) 0.75
Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol (2017) 0.75
An Umpolung Approach for the Chemoselective Arylation of Selenocysteine in Unprotected Peptides. J Am Chem Soc (2015) 0.75
A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl (2002) 24.12
Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci U S A (2007) 8.50
A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc (2004) 7.51
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J Am Chem Soc (2008) 5.52
Cu-free click cycloaddition reactions in chemical biology. Chem Soc Rev (2010) 3.89
Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 3.70
Second-generation difluorinated cyclooctynes for copper-free click chemistry. J Am Chem Soc (2008) 3.65
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol (2010) 2.67
Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol (2009) 2.41
Biomedical applications of tetrazine cycloadditions. Acc Chem Res (2011) 2.10
Bioconjugation with strained alkenes and alkynes. Acc Chem Res (2011) 1.89
Inverse-electron-demand Diels-Alder reaction as a highly efficient chemoselective ligation procedure: synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells. J Pept Sci (2009) 1.56
Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res (2011) 1.50
A decade of bioorthogonal chemistry. Acc Chem Res (2011) 1.32
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol (2009) 1.31
Surpassing the use of copper in the click functionalization of polymeric nanostructures: a strain-promoted approach. J Am Chem Soc (2009) 1.25
Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry (2009) 1.23
An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A (2008) 1.21
Strain-promoted alkyne azide cycloaddition for the functionalization of poly(amide)-based dendrons and dendrimers. J Am Chem Soc (2010) 1.07
Synthesis of a DOTA--biotin conjugate for radionuclide chelation via Cu-free click chemistry. Org Lett (2010) 0.94
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorg Med Chem Lett (2008) 0.90
Extension of the PNA world by functionalized PNA monomers eligible candidates for inverse Diels Alder Click Chemistry. Int J Med Sci (2010) 0.88
Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation. Tetrahedron Lett (2011) 0.83
Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery. J Med Chem (2000) 0.80
Testosteronyl-4-dimethylaminobutyrate-HCl: a prodrug with improved skin penetration rate. J Pharm Sci (1993) 0.78
Toxic antibodies blitz tumours. Nature (2011) 0.77
Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J (2006) 3.68
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood (2011) 2.09
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J Neurosci (2005) 1.93
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci U S A (2010) 1.51
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol (2011) 1.49
Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem (2005) 1.38
Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int J Cancer (2006) 1.37
Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 1.32
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood (2010) 1.30
Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol (2003) 1.30
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J Med Chem (2004) 1.29
2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. J Med Chem (2007) 1.26
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem (2002) 1.26
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem (2002) 1.25
Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem (2002) 1.25
Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry (2009) 1.23
Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol (2003) 1.22
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One (2011) 1.21
An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A (2008) 1.21
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc Natl Acad Sci U S A (2006) 1.16
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol (2012) 1.16
An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol Pharmacol (2009) 1.15
High-resolution structure of the Yersinia pestis protein tyrosine phosphatase YopH in complex with a phosphotyrosyl mimetic-containing hexapeptide. Biochemistry (2003) 1.14
Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. Proc Natl Acad Sci U S A (2004) 1.13
Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems. Restor Neurol Neurosci (2008) 1.12
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs (2006) 1.11
Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. J Neurosci (2009) 1.08
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles. Bioorg Med Chem Lett (2006) 1.06
Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction. Structure (2010) 1.04
Authentic HIV-1 integrase inhibitors. Future Med Chem (2010) 1.04
Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. Bioorg Med Chem Lett (2009) 1.04
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.04
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc Natl Acad Sci U S A (2007) 1.04
Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays. Mol Pharmacol (2006) 1.03
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J Comput Aided Mol Des (2005) 1.02
15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. Cancer Res (2007) 1.02
Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2003) 1.02
Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. Chembiochem (2012) 1.02
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother (2002) 1.01
Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci U S A (2001) 1.00
Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. J Mol Biol (2010) 1.00
Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J Immunol Methods (2004) 1.00
Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues. J Org Chem (2011) 1.00
Targeting malignant B cells with an immunotoxin against ROR1. MAbs (2012) 0.98
Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. ACS Chem Biol (2012) 0.96
Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. J Immunol Methods (2006) 0.96
Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol Appl Pharmacol (2002) 0.96
Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides. Bioorg Med Chem Lett (2007) 0.96
Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Mol Cancer Ther (2004) 0.95
Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res (2005) 0.95
Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase. J Med Chem (2011) 0.95
Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol (2008) 0.94
E. coli expression and purification of Fab antibody fragments. Curr Protoc Protein Sci (2009) 0.94
Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Bioorg Med Chem (2012) 0.94
Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic. Bioorg Med Chem (2005) 0.94
Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in hela cells. Biopolymers (2014) 0.93
Improving the serum stability of site-specific antibody conjugates with sulfone linkers. Bioconjug Chem (2014) 0.93
Metal-dependent inhibition of HIV-1 integrase. J Med Chem (2002) 0.92
Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents. Int J Pept Res Ther (2006) 0.92
Chemically programmed bispecific antibodies that recruit and activate T cells. J Biol Chem (2012) 0.92
Isolation of human prostate cancer cell reactive antibodies using phage display technology. J Immunol Methods (2004) 0.92
Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem (2003) 0.92
Isothiazolidinone (IZD) as a phosphoryl mimetic in inhibitors of the Yersinia pestis protein tyrosine phosphatase YopH. Acta Crystallogr D Biol Crystallogr (2011) 0.91
A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger. Angew Chem Int Ed Engl (2003) 0.91
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorg Med Chem Lett (2008) 0.90
Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Proc Natl Acad Sci U S A (2004) 0.90
SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization. Chembiochem (2008) 0.90
Ring-closing metathesis of C-terminal allylglycine residues with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic as an approach to novel Grb2 SH2 domain-binding macrocycles. Chembiochem (2005) 0.89
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One (2012) 0.89
Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells. Virology (2004) 0.89
Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem (2009) 0.89
Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorg Med Chem Lett (2012) 0.87
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther (2005) 0.87
Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site. J Biol Chem (2006) 0.87
Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. Chem Biol Drug Des (2011) 0.86
A rapid oxime linker-based library approach to identification of bivalent inhibitors of the Yersinia pestis protein-tyrosine phosphatase, YopH. Bioorg Med Chem Lett (2010) 0.86
Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality. Bioorg Med Chem (2009) 0.86
Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format. Methods Mol Biol (2012) 0.86
Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy. Chemistry (2004) 0.86
Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. J Mol Biol (2005) 0.86
Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides. J Med Chem (2003) 0.86